

# Anti-allergy properties of PRD-92-Ea [5,5-Dimethyl-11-oxo 5H, 11H-(2) benzopyrano (4,3-g) (1) benzopyran-9-carboxylic acid ethanolamine]

J.L. BEETS, H. MEADE & J. MORLEY

*Department of Clinical Pharmacology, Cardiothoracic Institute & Brompton Hospital, Fulham Road, London SW3 6HP*

PRD-92-Ea inhibits the PCA reaction in the rat when given by oral or intravenous routes (Stewart, Devlin & Freter, 1974). However, PRD-92-Ea has also been reported to antagonize *in vitro* 5-HT, bradykinin, SRS-A and histamine (Possanza, Bauen & Stewart, 1975). Therefore, the anti-allergy profile of this drug has been further investigated in the guinea-pig and rat using an isotopic method for measuring increased vascular permeability (Morley, Wolstencroft & Dumonde, 1973).

Guinea-pigs and rats received an intravenous injection of 1–2  $\mu$ Ci of [ $^{125}$ I]-HSA in 2% Evans Blue Dye. Inflammatory responses were elicited at 12 sites of flank skin by local injection of irritant (eg 48/80) or antigen (egg albumin in the rat and BGG in the guinea-pig) into passively sensitized sites. Drugs were given intravenously, orally or locally. The use of local administration of both antigen and drug permits dose response curves to anti-allergy drugs to be adequately defined with small numbers of animals.

In the guinea-pig PRD-92-Ea caused little inhibition of IgG mediated PCA reactions whereas in the rat reaginic PCA reactions were strongly inhibited by local ( $ED_{50} = 0.35 \mu\text{g/site}$ ) or systemic ( $ED_{50} = 0.5 \text{ mg/kg}$ ) administration. However, responses to 48/80

(1  $\mu\text{g/site}$ ) and peptide 401 (1  $\mu\text{g/site}$ ) were partially antagonized (up to 50%) in both species by local injection of PRD-92-Ea. Inflammatory responses in the guinea-pig to local administration of histamine (1  $\mu\text{g/site}$ ), 5-HT (60  $\mu\text{g/site}$ ) or bradykinin (0.5  $\mu\text{g/site}$ ) were not inhibited by local PRD-92-Ea up to a concentration of 2 mg/site. Similarly in the rat, comparable responses to these mediators were not antagonized by local injection of PRD-92-Ea up to 0.5 mg/site. Systemic injection of PRD-92-Ea (75 mg/kg) into guinea-pigs was found to reduce PCA, Arthus, 48/80, histamine and bradykinin reactions but such concentrations greatly exceeded the systemic doses which effectively inhibit rat PCA responses;  $ED_{50} = 0.5 \text{ mg/kg}$  (El-Azab & Stewart, 1977).

These properties of PRD-92-Ea are consistent with this drug acting *in vivo* specifically as an anti-allergy agent rather than as an antagonist of putative mediator responses.

We thank Boehringer Ingelheim for supplying PRD-92-Ea and for financial support.

## References

- EL-AZAB, J. & STEWART, P.B. (1977). Pharmacological profile of a new anti-allergic compound PRD-92-Ea. *Int. Arch. Allergy Appl. Immunol.* (In press).
- MORLEY, J., WOLSTENCROFT, R.A. & DUMONDE, D.C. (1973). The Measurement of Lymphokines. From: *Handbook of Experimental Immunology*, ed. Weir, D.M. 2nd edition. pp. 281.1–281.6. Oxford: Blackwells.
- POSSANZA, G.J., BAUEN, A. & STEWART, P.B. (1975). *In vitro* antagonism of the mediators of allergy by a benzopyrano-benzopyran carboxylic acid PRD-92-Ea. *Int. Arch. Allergy Appl. Immunol.*, **49**, 789.
- STEWART, P.B., DEVLIN, J.P. & FRETER, K.R. (1974). Anti-allergic activity of a benzopyran PRD-92-Ea. *Fed. Proc. Fed. Amer. Soc. exp. Biol.*, **33**, No. 3, Part I.

# Effects of D-penicillamine and levamisole on delayed hypersensitivity reactions in the rat and mouse

F.M. CUNNINGHAM, A.W. FORD-HUTCHINSON, M.J.H. SMITH & J.R. WALKER

*Biochemical Pharmacology Research Unit, Department of Chemical Pathology, King's College Hospital Medical School, Denmark Hill, London, SE5 8RX*

D-penicillamine and levamisole are antirheumatic drugs with a late onset of action and differ from conventional non-steroidal anti-inflammatory agents in showing no anti-inflammatory effects in animal

models (Huskinson, Dieppe, Scott, Trapnell, Balme & Willoughby, 1976). Their mode of action in rheumatoid arthritis is unknown but levamisole has been reported to stimulate both humoral and cell mediated immunity (Renoux & Renoux, 1972; Tripodi, Parkes & Brugmans, 1973). It has been suggested that D-penicillamine may possess similar immunostimulatory properties (Dieppe, Willoughby, Huskinson & Arrighoni-Martelli, 1976).

The effects of daily oral administration of 25 mg/kg D-penicillamine and 5 mg/kg levamisole upon delayed hypersensitivity reactions to *Bacillus pertussis* in the rat, and sheep red blood cells in the mouse were examined. Rats were implanted with sponges soaked in *B. pertussis* (Ford-Hutchinson, Smith, Elliott, Bolam, Walker, Lobo, Badcock, Colledge & Billimoria, 1975) having been sensitized twelve days